SEP 2 4 2003

510(k) Summary for the AURORA Magnetic Resonance Diagnostic Device (per 21CFR807.92)

1. Sponsor

Aurora Imaging Technology, Inc. 39 High Street North Andover, MA 01845

Contact Person: Vera Zhang

Telephone: 978

978-975-7530, ext. 4322

Date Prepared: August 27, 2003

2. DEVICE NAME

Proprietary Name: AURORA

Common/Usual Name: Magnetic resonance imaging device Classification Name: Magnetic resonance diagnostic device

3. PREDICATE DEVICES

AURORA MRI system (K032082)

4. **DEVICE DESCRIPTION**

The modified AURORA is identical to the AURORA breast imaging system cleared by FDA through K032082 except for the addition of the RODEO fat-suppression pulse sequence.

5. Intended Use

The AURORA MRI system is an imaging device, and is intended to provide the physician with physiological and clinical information obtained non-invasively and without the use of ionizing radiation. The MR system produces transverse, coronal, sagittal, and oblique cross-sectional images that display the internal structure of the extremities (breast tissue, axilla, and chest wall local to the breast). The images produced by the MR system reflect the spatial distribution of protons (hydrogen nuclei) exhibiting magnetic resonance. The NMR properties that determine the

image appearance are proton density spin-lattice relaxation time (T1), spin-spin relaxation time (T2), and flow. When interpreted by a trained physician, these images provide information that can be useful in diagnosis determination.

The AURORA is a dedicated breast MRI system intended to be used as an adjunct to conventional breast screening methods.

• Anatomical region: Breast tissue, axilla, and chest wall local to the

breast

Nucleus excited: Proton

• Diagnostic uses: 2D, 3D T1- / T2-weighted imaging

TI, T2, proton density measurements

Image processing

• Imaging capabilities: 2D Spin Echo (SE)

2D/3D Gradient Echo (GRE)

Fat Suppression

Imaging processing: Image Subtraction

Image Filtering

6. TECHNOLOGICAL CHARACTERISTICS AND SUBSTANTIAL EQUIVALENCE

Aurora Imaging Technology, Inc., makes a claim of substantial equivalence of the modified AURORA to the predicate AURORA (K032082) based on similarities in intended use, design, and technological and operational characteristics. Both are indicated for magnetic resonance imaging of the breast. Both systems use the same hardware and software except that the modified device includes a new pulse sequence for fat suppression.

7. TESTING

Testing was performed to validate the safety and performance of the AURORA with the new pulse sequence.



SEP 2 4 2003

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Aurora Imaging Technology, Inc. % Mr. James R. Veale
Vice President, Strategic
And Technical Assistance
Medical Device Consultants, Inc.
49 Plain Street
NORTH ATTLEBORO MA 02760

Re: K032678

Trade/Device Name: AURORA MRI System Regulation Number: 21 CFR 892.1000 Regulation Name: Magnetic resonance

diagnostic device

Regulatory Class: II Product Code: 90 LNH Dated: August 27, 2003 Received: August 29, 2003

Dear Mr. Veale:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at one of the following numbers, based on the regulation number at the top of the letter:

8xx.1xxx	(301) 594-4591
876.2xxx, 3xxx, 4xxx, 5xxx	(301) 594-4616
884.2xxx, 3xxx, 4xxx, 5xxx, 6xxx	(301) 594-4616
892.2xxx, 3xxx, 4xxx, 5xxx	(301) 594-4654
Other	(301) 594-4692

Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97) you may obtain. Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html.

Sincerely yours,

Mancy C. Brogdon
Nancy C. Brogdon

Director, Division of Reproductive, Abdominal and Radiological Devices

Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure

510(k) Number:

Device Name: AURORA

Indications for Use:

The AURORA MRI system is an imaging device, and is intended to provide the physician with physiological and clinical information obtained non-invasively and without the use of ionizing radiation. The MR system produces transverse, coronal, sagittal, and oblique crosssectional images that display the internal structure of the extremities (breast tissue, axilla, and chest wall local to the breast). The images produced by the MR system reflect the spatial distribution of protons (hydrogen nuclei) exhibiting magnetic resonance. The NMR properties that determine the image appearance are proton density spin-lattice relaxation time (T1), spin-spin relaxation time (T2), and flow. When interpreted by a trained physician, these images provide information that can be useful in diagnosis determination.

The AURORA is a dedicated breast MRI system intended to be used as an adjunct to conventional breast screening methods.

Anatomical region:

Breast tissue, axilla, and chest wall local to the breast

Nucleus excited:

Proton

Diagnostic uses:

2D, 3D T1- / T2-weighted imaging

TI, T2, proton density measurements Image processing

Imaging capabilities: 2D Spin Echo (SE)

2D/3D Gradient Echo (GRE)

Fat Suppression

Imaging processing: Image Subtraction

Image Filtering

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NECESSARY)

Concurrence of CDRH, Office of Device Evaluation (ODE)

(Division Sign-Off)

Division of Reproductive, Abdominal,

and Radiological Devices

510(k) Number

Prescription Use \(\forall \) (Per 21 CFR 801.109)

OR

Over-The-Counter Use

(Optional Format 1-2-96)